Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest EPS Growth Forecast For Next 5 Years

Below are the top drugs-generic stocks on the NASDAQ in terms of EPS growth forecast for the next five years.

Evoke Pharma Inc (NASDAQ: EVOK) earnings per share growth forecast for the next five years is 40.00 percent. Evoke Pharma has a market capitalization of $33.54 million.

Steadymed Ltd (NASDAQ: STDY) EPS growth forecast for the next five years is 37.50 percent. Steadymed's trailing-twelve-month EPS is -$1.78.

Sagent Pharmaceuticals Inc (NASDAQ: SGNT) EPS growth forecast for the next five years is 26.68 percent. Sagent Pharmaceuticals' PEG ratio is 0.91.

Akorn, Inc. (NASDAQ: AKRX) earnings per share growth forecast for the next five years is 23.72 percent. Akorn's trailing-twelve-month ROE is 11.10 percent.